SBFMW — Sunshine Biopharma Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1402328 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 9,263,687 2,426,682 -1,612,858 -1,564,048 33,632,901 13,748,301 6,094,899
Mar 2026 8,088,765 2,180,990 -1,395,597 -1,243,869 27,930,375 6,913,013 6,413,781
Dec 2025 8,577,141 3,028,845 -1,658,223 -2,140,927 30,079,167 9,123,308 7,040,707
Sep 2025 9,417,179 3,073,540 -531,963 -883,820 31,487,379 9,306,438 7,288,023

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,352,750
Investing CF
$-183,740
Financing CF
$8,528,685
CapEx
$-183,740
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-77,823,043
Inventory
$12,121,796
Receivables
$4,035,360
ST Investments
—
EBIT TTM
$-5,762,266
Pretax Income TTM
$-5,561,728
Interest Exp TTM
$0
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$35,371,920
EBITDA
$-5,629,057
Free Cash Flow
$-2,762,243
Enterprise Value
—
Total Cash
$15,041,494
Total Debt
$627,565
Shares Out
—
Trailing EPS
$-2.21
Book Value
$102.85
ROE
-23.4%
ROA
-11.4%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 36,305,891 -4,478,782 -5,975,352 30,079,167 7,040,707 23,038,460 -5,331,073
Dec 2024 34,874,283 -5,812,121 -5,134,116 30,560,392 7,059,638 23,500,754 -12,524,779
Dec 2023 24,092,787 -4,785,299 -4,506,044 27,346,961 6,139,600 21,207,361 -8,775,111
Dec 2022 4,345,603 -8,674,031 -26,744,440 29,243,848 7,616,278 21,627,570 -5,248,358

TTM Snapshot

Revenues TTM
$35,346,772
NetIncome TTM
$-5,832,664
OpCashFlow TTM
—
Assets (Latest)
$33,632,901
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $1.26T $1415.55 —
JNJ JOHNSON & JOHNSON $670.92B $278.70 —
ABBV AbbVie Inc. $517.59B $292.82 —
MRK Merck & Co., Inc. $353.44B $143.37 —
NVS NOVARTIS AG $302.46B $159.13 —

News headlines (Yahoo Finance, 1h cache)

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
2026-07-20 12:30 · Yahoo
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
2026-10-22 13:00 · Yahoo
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
2026-10-09 15:17 · Yahoo
Sunshine Biopharma Prices $6 Million Public Offering at $0.55 Per Unit, Raising Dilution Concerns
2026-10-08 14:40 · Yahoo
BC-Most Active Stocks
2026-10-08 14:30 · Yahoo
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
2026-10-08 12:00 · Yahoo
Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know
2026-09-24 15:00 · Yahoo
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
2026-09-24 13:00 · Yahoo
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
2026-09-16 13:00 · Yahoo
EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies
2026-09-16 12:31 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.